Phase 2 Trial of V-5 Immunitor (V5) in Patients with Chronic Hepatitis C Co-infected with HIV and Mycobacterium tuberculosis

Trial Profile

Phase 2 Trial of V-5 Immunitor (V5) in Patients with Chronic Hepatitis C Co-infected with HIV and Mycobacterium tuberculosis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2010

At a glance

  • Drugs Ethambutol; Hepcortespenlisimut-L; Isoniazid; Pyrazinamide; Rifampicin; Streptomycin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Immunitor
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top